Executive VP, Preclinical Development

Nancy Agrawal, PhD

Nancy has more than 25 years of drug discovery and development experience across multiple therapeutic areas, including antivirals. Nancy has extensive experience leading pharmacokinetics, pharmacodynamics, and drug metabolism groups, spanning ADME, bioanalytics, quantitative pharmacology/pharmacometrics, and operations. 

Prior to joining Atea, Nancy spent more than 25 years in roles of increasing responsibility at Merck & Inc., most recently as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism. Prior roles at Merck & Co. included Associate Vice President of Formulation Sciences, Associate Vice President of Biopharmaceutics and Specialty Dosage Forms and Associate Vice President of Preclinical Absorption, Distribution, Metabolism, and Excretion. 

Nancy holds a BS degree in Chemical Engineering from Kansas State University and MS and PhD degrees in Chemical Engineering from the University of Michigan.

Back to Full Team
Nancy Agrawal, PhD